Caprion Buys PPD's Biomarker Business | GenomeWeb

NEW YORK (GenomeWeb News) – Caprion Proteomics said today that it has acquired the biomarker services division of PPD, a contract research firm focused on pharmaceutical services based in Wilmington, NC, for an undisclosed sum.

Montreal-based Caprion said that it closed the acquisition of PPD Biomarker Discovery Services on December 31, 2009.

Caprion said that it will fulfill PPD’s existing contractual biomarker obligations from its Montreal facilities and from a new US facility to be called Caprion Proteomics, US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.